Gamma oscillations in the mPFC: A potential predictive biomarker of depression and antidepressant effects.

Antidepressants Depression Gamma oscillations Ketamine mPFC

Journal

Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617

Informations de publication

Date de publication:
08 Nov 2023
Historique:
received: 21 08 2023
revised: 06 11 2023
accepted: 06 11 2023
pubmed: 11 11 2023
medline: 11 11 2023
entrez: 10 11 2023
Statut: aheadofprint

Résumé

Gamma oscillations have attracted much attention in the field of mood disorders, but their role in depression remains poorly understood. This study aimed to investigate whether gamma oscillations in the medial prefrontal cortex (mPFC) could serve as a predictive biomarker of depression. Chronic restraint stress (CRS) or lipopolysaccharide (LPS) were used to induce depression-like behaviors in mice; local field potentials (LFPs) in the mPFC were recorded by electrophysiological techniques; We found that both CRS and LPS induced significant depression-like behaviors in mice, including increasing immobility durations in the forced swimming test (FST) and tail suspension test (TST) and increasing the latency to feed in the novelty-suppressed feeding test (NSFT). Electrophysiological results suggested that CRS and LPS significantly reduced low and high gamma oscillations in the mPFC. Furthermore, a single injection of ketamine or scopolamine for 24 h significantly increased gamma oscillations and elicited rapid-acting antidepressant-like effects. In addition, fluoxetine treatment for 21 days significantly increased gamma oscillations and elicited antidepressant-like effects. Taken together, our findings suggest that gamma oscillations are strongly associated with depression, yielding new insights into investigating the predictive biomarkers of depression and the time course of antidepressant effects.

Identifiants

pubmed: 37949392
pii: S0278-5846(23)00179-3
doi: 10.1016/j.pnpbp.2023.110893
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110893

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there are no conflicts of interest.

Auteurs

Yong-Yu Yin (YY)

Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing, China. Electronic address: 472586836@qq.com.

Jiao-Zhao Yan (JZ)

Beijing Institute of Basic Medical Sciences, Beijing, China.

Shi-Xin Lai (SX)

School of Medicine, Sun Yat-Sen University, Shenzhen campus, Shenzhen, China.

Qian-Qian Wei (QQ)

School of Medicine, Nantong University, Nantong, China.

Si-Rui Sun (SR)

Beijing Ditan Hospital Capital Medical University, Beijing, China.

Li-Ming Zhang (LM)

Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing, China.

Yun-Feng Li (YF)

Beijing Institute of Pharmacology and Toxicology, State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing, China; Beijing Institute of Basic Medical Sciences, Beijing, China. Electronic address: lyf619@aliyun.com.

Classifications MeSH